Interested in learning about our Gen 3 Library Platform? Our webinar “High Quality #Antibodies Straight From Selections” shares how the platform offers developability, extremely high diversity & the exclusion of sequence liabilities. #biotech ow.ly/Mcr150D5L7n
Specifica
@SpecificaInc
Specifica empowers companies that create cures with visionary antibody technologies.
82 Following 36 Followers 94 Posts
Latest posts 5
Our mission is to empower companies with visionary #antibody technologies. By using Next Generation Sequencing (#NGS) throughout construction & output analyses, we can directly measure the diversity of each exclusive library we build. #biotech
ow.ly/FACp50Dk9jQ
ow.ly/FACp50Dk9jQ
Via @GENbio, a look at #monoclonalantibodies, their biological complexities & the innovative new approaches for production and use, as the global therapeutic monoclonal #antibody market is expected to generate revenue of $300B by 2025. #biotech #antibodies ow.ly/g4Ew50Dk7Z3
Why choose the Specifica platform? With visionary #antibody technologies, we're focused on empowering you to generate antibody drugs against any target, to create cures for any disease with our exceptional, exclusive #AntibodyLibraries. #antibodies
ow.ly/8ZRn50DbA1Y
ow.ly/8ZRn50DbA1Y
.@NewsMedical shared new research on #SARSCoV2, showing how closely the #antibodies formed in exposed humans resemble germline #antibody molecules which could lead to the development of novel antibody #therapeutics to counter the #pandemic. #covid19
ow.ly/DH6D50Dbzo6
ow.ly/DH6D50Dbzo6